EP0682519A4 - Adenosinkinaseinhibitoren. - Google Patents

Adenosinkinaseinhibitoren.

Info

Publication number
EP0682519A4
EP0682519A4 EP94909558A EP94909558A EP0682519A4 EP 0682519 A4 EP0682519 A4 EP 0682519A4 EP 94909558 A EP94909558 A EP 94909558A EP 94909558 A EP94909558 A EP 94909558A EP 0682519 A4 EP0682519 A4 EP 0682519A4
Authority
EP
European Patent Office
Prior art keywords
kinase inhibitors
adenosine kinase
adenosine
inhibitors
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94909558A
Other languages
English (en)
French (fr)
Other versions
EP0682519A1 (de
Inventor
Gary Steven Firestein
Bheemarao Ganapatrao Ugarkar
Leonard Paul Miller
Harry Edward Gruber
David Andrew Bullough
Mark David Erion
Angelo John Castellino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sicor Inc
Original Assignee
Sicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sicor Inc filed Critical Sicor Inc
Publication of EP0682519A1 publication Critical patent/EP0682519A1/de
Publication of EP0682519A4 publication Critical patent/EP0682519A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP94909558A 1993-02-03 1994-02-03 Adenosinkinaseinhibitoren. Withdrawn EP0682519A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1419093A 1993-02-03 1993-02-03
PCT/US1994/001340 WO1994017803A1 (en) 1993-02-03 1994-02-03 Adenosine kinase inhibitors
US14190 2001-11-13

Publications (2)

Publication Number Publication Date
EP0682519A1 EP0682519A1 (de) 1995-11-22
EP0682519A4 true EP0682519A4 (de) 1997-12-17

Family

ID=21764031

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94909558A Withdrawn EP0682519A4 (de) 1993-02-03 1994-02-03 Adenosinkinaseinhibitoren.

Country Status (4)

Country Link
EP (1) EP0682519A4 (de)
AU (1) AU6236594A (de)
IL (1) IL108523A0 (de)
WO (1) WO1994017803A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763597A (en) * 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5763596A (en) * 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5721356A (en) * 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5864033A (en) * 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5674998A (en) * 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
US5665721A (en) * 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
TW427996B (en) * 1995-07-11 2001-04-01 Astra Pharma Prod Novel triazolopyrimidines and their use as medicaments
AU1441497A (en) * 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
JP4255138B2 (ja) * 1996-05-24 2009-04-15 湧永製薬株式会社 脳疾患治療剤
WO1998001459A1 (en) * 1996-07-05 1998-01-15 Novo Nordisk A/S Novel n-alkoxyadenine derivatives acting as cytokine inhibitors
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
CA2234342A1 (en) * 1997-04-10 1998-10-10 Kyowa Hakko Kogyo Co., Ltd. Pancreatitis remedy
ID29028A (id) * 1998-09-18 2001-07-26 Basf Ag Pirolopirimidina sebagai penghambat protein kinase
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
JP2003509428A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
BR0016415A (pt) * 1999-12-16 2002-12-24 Alcon Inc Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico
AU2000240570A1 (en) * 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
WO2004092173A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
EP1831225A2 (de) * 2004-11-19 2007-09-12 The Regents of the University of California Entzündungshemmende pyrazolopyrimidine
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
US8637485B2 (en) * 2007-08-02 2014-01-28 Southern Research Institute 5′,-substituted adenosynes preparation thereof and use as inhibitors of S-adenosylmethionine decarboxylase
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
PT2231689T (pt) * 2008-01-18 2016-10-07 Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic Novos nucleósidos 7-deazapurina citostáticos
EP2252293B1 (de) 2008-03-14 2018-06-27 Intellikine, LLC Kinasehemmer und verwendungsverfahren
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
GB0815968D0 (en) * 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
KR20110063447A (ko) 2008-09-08 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
EP2358720B1 (de) 2008-10-16 2016-03-02 The Regents of The University of California Heteroarylkinasehemmer mit kondensierten ringen
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP2012521359A (ja) * 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
PT2421879E (pt) * 2009-04-22 2013-12-09 Acad Of Science Czech Republic Novos 7-deazapurina nucleósidos para utilizações terapêuticas
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2603511B1 (de) 2010-08-12 2017-03-15 Boehringer Ingelheim International GmbH 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-on derivate und ihre verwendung als pde9a inhibitoren
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2014277740B1 (en) * 2014-12-17 2016-02-25 Institute of Organic Chemistry and Biochemistry, ASCR, v.v.i. Novel substituted 7-deazapurine ribonucleosides for therapeutic uses
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
EP3170830A1 (de) * 2015-11-17 2017-05-24 Centre National De La Recherche Scientifique Neue 5-azido-5-deoxy-2:3-isopropyliden-d-arabinose-verbindungen; verfahren zu deren herstellung und deren verwendung zur synthese von ara-n3, kdo-n3 und 4ekdo-n3
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
WO2018094148A1 (en) * 2016-11-18 2018-05-24 Arcus Biosciences, Inc. Inhibitors of cd73-mediated immunosuppression
CN110687232A (zh) * 2018-07-04 2020-01-14 郑州泰丰制药有限公司 用高效液相色谱检测l-氯糖差向异构体的方法
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
WO2024134541A1 (en) * 2022-12-20 2024-06-27 iTeos Belgium SA Heterocyclic compounds as ent inhibitors and compounds for use in the treatment of cancers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009163A2 (en) * 1989-01-24 1990-08-23 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
WO1992002214A1 (en) * 1990-08-10 1992-02-20 Gensia Pharmaceuticals, Inc. Aica riboside analogs
WO1994006438A1 (en) * 1992-09-11 1994-03-31 The Regents Of The University Of California Adenosine analogues and method of increasing adenosine release

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009163A2 (en) * 1989-01-24 1990-08-23 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
WO1992002214A1 (en) * 1990-08-10 1992-02-20 Gensia Pharmaceuticals, Inc. Aica riboside analogs
WO1994006438A1 (en) * 1992-09-11 1994-03-31 The Regents Of The University Of California Adenosine analogues and method of increasing adenosine release

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COTTAM ET AL.: "New Adenosine Kinase Inhibitors with Oral Antiinflammatory Activity: Synthesis and Biological Evaluation.", J. MED. CHEM., vol. 36, 1993, P0C038, pages 3424 - 3430, XP000573807 *
GLORIOSO ET AL.: "Double-blind Multicentre Study of the Activity of S-adenosylmethionine in Hip and Knee Osteoarthritis.", INT. J. CLIN. PHARM. RES., vol. 5, no. 1, 1985, pages 39 - 49, XP000673760 *
See also references of WO9417803A1 *

Also Published As

Publication number Publication date
WO1994017803A1 (en) 1994-08-18
IL108523A0 (en) 1994-05-30
EP0682519A1 (de) 1995-11-22
AU6236594A (en) 1994-08-29

Similar Documents

Publication Publication Date Title
EP0682519A4 (de) Adenosinkinaseinhibitoren.
ZA9410139B (en) Protein kinase C inhibitors
EP0608897A3 (en) Tyrosine kinase inhibitors and benzoylacrylamide derivatives.
IL122335A0 (en) C-4' adenosine kinase inhibitors
GR3029455T3 (en) 3-Aryl-4-hydroxy-3-dihydrofuranone derivatives.
EP0634718A3 (de) Rechnersystemsintegrierung.
EP0601322A3 (de) Adenosindeaminaseinhibitor.
EP0620222A3 (de) Tetrahydro-betacarboline.
EP0641704A3 (de) Einzelrad-Schlitten.
AU7467294A (en) Tyrosine kinase inhibitor
EP0620223A3 (de) Tetrahydropyridoindol.
ZA941137B (en) Substitutet azolone derivatives.
ZA946728B (en) Tocopherois.
ZA929768B (en) 5-isoquinolinesulfonamide derivatives as protein kinase inhibiting agents.
GR3032441T3 (en) Bit synchronizer
EP0620043A3 (de) Zerkleinerungsapparat für feste Gegenstände.
EP0609763A3 (en) Ph-glasselectrode.
EP0657193A3 (de) Skibremse.
ZA936239B (en) Shotgun
ZA949611B (en) Protein kinase C inhibitors
EP0643916A3 (de) Choux-Mischungen.
EP0645218A3 (de) Werkzeugschaft.
ZA948297B (en) Pyrimidine derivatives
ZA931109B (en) Tetrahydropyrimidine derivatives.
EP0682714A4 (de) Neuartiger hemmstoff für neutro-phile.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB IT LI

A4 Supplementary search report drawn up and despatched

Effective date: 19971031

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE FR GB IT LI

17Q First examination report despatched

Effective date: 19990331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010426